VBC103

VelaVigo Bio Inc · Phase 1 active Small molecule

At a glance

Generic name	VBC103
Sponsor	VelaVigo Bio Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VBC103 CI brief — competitive landscape report
VBC103 updates RSS · CI watch RSS
VelaVigo Bio Inc portfolio CI